Ads like these are all over social media. Too often, doctors warn, the companies behind the ads appear to prioritize business ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...

In her last week at AdExchanger, Senior Editor Alyssa Boyle reflects on three years of change, and stasis, in the CTV space.

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions ...

A fast-growing body of research signals potential health benefits of GLP-1s, the class of diabetes and weight-loss drugs known by names like Ozempic, beyond what they were initially approved to treat.

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Some people have critiqued Ozempic (semaglutide)—a diabetes medication that can aid in weight loss—for the effects it has on the skin. Some people have reported "Ozempic face" and "Ozempic ...

Ozempic and Wegovy, the widely popular forms ... its sale of compounded GLP-1 drugs in a 60-second Super Bowl ad earlier this month, drawing some scrutiny and criticisms. The company bought ...

The Food and Drug Administration said Friday the shortage of Ozempic and Wegovy is over ... its weight-loss offerings in a Super Bowl ad as “affordable” and “doctor-trusted,” while ...